Mark J. Rosenblum - 20 Nov 2025 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Exec VP Finance, CFO
Signature
/s/ Mark J. Rosenblum
Issuer symbol
SLRX
Transactions as of
20 Nov 2025
Net transactions value
+$16,000
Form type
4
Filing time
20 Nov 2025, 16:42:09 UTC
Previous filing
22 Feb 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rosenblum Mark J Exec VP Finance, CFO C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON /s/ Mark J. Rosenblum 20 Nov 2025 0001329154

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Purchase $16,000 +20,000 +11299% $0.8000 20,177 20 Nov 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.
F2 Includes 20 shares of unvested restricted stock granted on January 3, 2023.